Streptococcus pneumoniae whole-cell antigens (S. pneumoniae WCA)

Streptococcus pneumoniae whole-cell antigens consist of a diverse array of conserved proteins and cellular structures derived from inactivated, non-encapsulated pneumococcal strains (Lu et al., 2010, Expert Rev Vaccines). These antigens are designed to elicit a broad-spectrum immune response that transcends the limitations of serotype-specific capsular vaccines (WHO, 2019). Biologically, they function by presenting multiple epitopes to the host immune system, including critical surface proteins like Pneumococcal surface protein A (PspA) and Pneumolysin (Ply). The primary mechanism of action involves the induction of Th17-mediated cellular immunity, which facilitates the clearance of pneumococcal colonization from the nasopharynx through neutrophil recruitment (Maluquer de Motes et al., 2004). Additionally, they stimulate the production of antibodies that can neutralize toxins and enhance opsonophagocytosis. This approach is particularly relevant for preventing invasive pneumococcal diseases such as pneumonia, meningitis, and sepsis, especially in regions where serotype diversity is high (PATH, 2020). By targeting conserved components, these antigens aim to provide universal protection and mitigate the issue of serotype replacement.

Other names

Pneumococcal whole-cell antigensWhole-cell pneumococcal vaccine antigensS. pneumoniae WCVKilled whole-cell pneumococcal antigens

Induction of broad-spectrum immunity through the presentation of conserved sub-capsular antigens, primarily eliciting a Th17-mediated cellular response and production of antibodies against surface proteins to prevent nasopharyngeal colonization and invasive disease (Lu et al., 2010; PATH, 2020).